Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Head and Neck
Lung Cancers
Prostate Cancer
Kidney Cancer
Precision Medicine
Supportive Care
Soft Tissue Sarcoma
Giants Cancer Care
Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.
Peter Voorhees, MD, associate professor, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the triplet regimen of pomalidomide, dexamethasone, and ixazomib in patients with double refractory multiple myeloma.
Steven I. Park, MD, director, Lymphoma Program, associate professor of Medicine, Leukemia, Lymphoma, and Myeloma Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Clinical Research, discusses how alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma cells.
The primary analysis of the phase III CALGB 40601 trial found that pathologic complete response to dual HER2 blockade was not statistically higher than anti-HER2 monotherapy. However, there was a high level of intertumoral heterogeneity, and patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy.
Jason Matney, PhD, clinical assistant professor, Physics and Computing Division, Department of Radiation Oncology, UNC School of Medicine, discusses a prospective assessment of deep inspiration breath hold to prevent radiation-associated cardiac perfusion defects in patients with left-sided breast cancer.
View more articles >>